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This work aimed to characterize mortality by sickle cell disease in Brazil. The MEDLINE
electronic database was searched using the terms ‘mortality’ and ‘sickle cell disease’ and
‘Brazil’ for articles published in the last ﬁve years aiming to provide a current analysis of
the  subject in question. Eight studies on mortality by sickle cell disease were carried out in
the  Brazilian states of Maranhão, Bahia, Minas Gerais, Rio de Janeiro and Mato Grosso do
Sul.  The majority of the deaths occurred in patients with sickle cell anemia, which is the
most common genotype and causes the most severe clinical manifestation of the disease.
In  summary, there are few published studies on mortality related to sickle cell disease in
Brazil, and most are from the state of Minas Gerais. This study emphasizes the importance of
developing more studies on sickle cell disease mortality, so that it may be possible to proﬁle
gene carriers and give health professionals more data to strategize the delivery of more
effective assistance to these individuals. Despite the early diagnosis of sickle cell disease
by  the Neonatal Screening Program and the use of preventive and therapeutic measures
(penicillin, immunization and hydroxyurea), mortality by sickle cell disease on the world
stage is still signiﬁcant.© 2016 Published by Elsevier Editora Ltda. on behalf of Associac¸a˜o Brasileira de
Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC
Y-NC
in the state of Minas Gerais.
SCD predominantly occurs in Afro-descendants; how-B
ntroduction
ickle cell disease (SCD) is a generic term used to deﬁne a
roup of genetic changes characterized by the dominance of
emoglobin S (Hb S). These changes include sickle cell anemia
Hb SS) and double heterozygosis, that is, associations of Hb SPlease cite this article in press as: Arduini GA, et al. Mortality by 
http://dx.doi.org/10.1016/j.bjhh.2016.09.008
ith other hemoglobin variants, such as Hb D and Hb C, and
nteractions with thalassemia (Hb S/  thalassemia, Hb S/+
halassemia, and Hb S/0 thalassemia). Hb S is characterized
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by a missense mutation in position 6 of the  chain, in
which the amino acid glutamic acid is replaced by  valine
(6 GLU→VAL).1 It was introduced in Brazil by the slave trade of
Negroes during the colonial period, mainly for sugarcane plan-
tations in the Northeast and, later, to extract precious metals
2,3sickle cell disease in Brazil. Rev Bras Hematol Hemoter. 2016.
UFTM), Instituto de Ciências Biológicas e Naturais/ICBN, Departa-
us I. Prac¸a Manoel Terra, 330, 38015-050 Uberaba, MG, Brazil.
i).
ever, it is not exclusive to this population due to evident
racial admixture in Brazil. About 34% of the investigated
ciac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular.
eativecommons.org/licenses/by-nc-nd/4.0/).
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individuals with SCD reported being victims of prejudice due
to the disease and 48.3% reported a connection between the
disease and their skin color.4 Predominance of Black ethnicity,
low education levels and income was observed in studies that
characterized the sociodemographic proﬁle of patients with
SCD in Brazil.5,6 In Brazil, the incidence of SCD is approx-
imately 1–3/1000 live births and in states such as Bahia,
where African ancestry predominates, this rate reaches 1/650
newborns.7
Signs and symptoms of SCD include hand–foot syndrome,
chronic hemolytic anemia, vaso-occlusive crises, infections,
acute chest syndrome (ACS), acute splenic sequestration
(ASS), stroke, priapism and leg ulcers.1,8 It is a chronic
genetic pathology, which negatively affects the quality of
life of individuals and their families.6,9,10 It exhibits autoso-
mal  recessive inheritance and, therefore, affected individuals
are homozygous for Hb S (Hb SS). Heterozygous individu-
als (Hb AS) have the sickle cell trait (SCT), that is, they are
mutant allele carriers, which can be transmitted to their
descendants.1 For couples in whom both individuals have
the SCT, identiﬁcation of the condition and genetic coun-
seling are important before starting a family.11 Difﬁculty
in distinguishing between the terms carrier and affected
individuals was reported in two recent researches.12,13 One
showed that only 17 (14.3%) of the 119 mothers whose
children presented an abnormal result in the screening
test for hemoglobinopathies could acknowledge the dif-
ference between the trait and the disease.13 The other,
with 136 educators (94.9% teachers) of public schools in
Montes Claros, Minas Gerais, revealed that 64.7% stated
there was no difference between SCD and SCT, highlighting
that this doubt exists even in people with higher lev-
els of education.12 Another unexpected ﬁnding was that
39% thought that SCD was a consequence of a lack of
nutrients.12
Due to its prevalence and clinical importance, SCD is
considered a public health problem in Brazil, and there-
fore public policies were implemented, including the Sickle
Cell Disease Program14 and National Policy for Comprehen-
sive Care of Persons with Sickle Cell Disease and Other
Hemoglobinopathies,15 aimed at providing better assistance
to affected individuals. Another advance was the early diag-
nosis of SCD and other hemoglobinopathies by the Guthrie
test, established by Government Decree of the Ministry of
Health n◦ 822, dated June, 6, 2001, which instituted the
National Neonatal Screening Service.16 Historic evolution of
the creation process of neonatal screening around the world,
in particular in Brazil, was reviewed by Rodrigues et al.2
Inclusion of SCD in the National Neonatal Screening Service
was of utmost importance because affected individuals do
not present clinical signs at birth, making early diagnosis
essential.
Therapeutic options available for SCD include bone marrow
transplantation, chronic transfusions and hydroxyurea (HU).
Studies with patients using HU showed signiﬁcant reduc-
tions in vaso-occlusive crises, ACS, infections, hospitalizations
and the number of transfusions.17,18Please cite this article in press as: Arduini GA, et al. Mortality by 
http://dx.doi.org/10.1016/j.bjhh.2016.09.008
This work aimed to characterize mortality by sickle cell
disease in Brazil in respect to the frequency, death rate or
mortality coefﬁcient, age and causes. 0 1 6;x  x x(x x):xxx–xxx
Methods
The MEDLINE electronic database was searched using the
terms ‘mortality’ and ‘sickle cell disease’ and ‘Brazil’ over the
last ﬁve years aiming to provide a current analysis of the
subject in question. Fifteen papers were identiﬁed, of which
only seven were selected based on the title and abstract.
Case reports were excluded and only those that were pub-
lished as full-length articles in English were considered. Other
databases, such as SciELO and BIREME, were also searched, but
the same articles were found. The reference lists of the articles
were systematically searched in order to identify any potential
additional studies that could be included. Eight studies were
included in this systematic review.
Results
Eight studies on mortality by SCD were carried out in the
Brazilian states of Maranhão,19 Bahia,20 Minas Gerais,21–23 Rio
de Janeiro24,25 and Mato Grosso do Sul.26
The study carried out in Maranhão assessed the impact of
the implementation of neonatal screening on hospitalization
and death rates due to SCD. The mortality rate increased from
0.115 to 0.216, that is 1.88 times higher, but this was not statis-
tically signiﬁcant (p-value = 0.586) and the median age at death
increased from 10 years to 14 years (p-value = 0.665).19
A recent research carried out in Bahia, the Brazilian state
with the largest black population and highest prevalence of
SCD, described the epidemiological proﬁle of the deaths by
SCD and reported 74 deaths in 2011 corresponding to a mortal-
ity coefﬁcient of 0.54 per 100,000 individuals.20 Yet, the causes
of death were not speciﬁed. About 42% of the deaths occurred
in adults (age range: 20–39 years). The majority of the deaths
(n = 64; 86.4%) occurred in hospital with Salvador being the city
with the highest number (14 deaths; 18.9%).20
The mortality and survival of children with SCD were inves-
tigated in Minas Gerais.21,22 Between 1998 and 2012, 2591
children were diagnosed with SCD (1:1.400). There were 193
deaths (7.4%): 153 (79.3%) children had Hb S/0 thalassemia,
34 (17.6%) had Hb SC and six (3.1%) had Hb S/+ thalassemia.
Of the deaths, 56.5% occurred in children under the age of two
and 76.7% in under ﬁve-year olds. The main causes of death
were infection (45%), indeterminate (28%) and ASS (14%).21
The term ‘sickle cell’ was not cited in 46% of death certiﬁ-
cates. The mortality rate between 1998 and 2005 was 5.43% vs.
5.12% between 2005 and 2012.21 Another study showed that
the 5-year estimated mortality was lower, albeit not signiﬁ-
cantly, for children born between 2009 and 2011 (n = 509) than
for those born between 1999 and 2001 (n = 624) [mean (standard
deviation): 5.8% (1.1) vs. 6.2% (1.0), respectively].22
Of the 912 newborns with SCD (639 with Hb SS, 201 with Hb
SC, 26 with Hb SD and 46 with Hb S/+-thal) in Rio de Janeiro
referred for treatment in the Fundac¸ão Hemorio in the period
from 2000 to 2010, 34 children (3.7%) died due to ACS (n = 14;
24sickle cell disease in Brazil. Rev Bras Hematol Hemoter. 2016.
Two studies analyzed the effect of HU therapy in patients
with SCD.25,26 A total of 267 children were treated with hydrox-
ycarbamide therapy for two years with a total of 38 deaths.
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he causes of death were ACS (n = 17; 45%), infection/sepsis
n = 13; 34%), stroke (n = 4; 10%), death during painful episodes
n = 3; 8%) and one death was unrelated to SCD (3%). There
ere 36 deaths among non-hydroxycarbamide users and only
ne among hydroxycarbamide users (2 = 4.57; p-value = 0.03).
urvival among hydroxycarbamide-treated children was sig-
iﬁcantly greater than that among untreated patients (99.5%
s. 94.5%; p-value = 0.01).25 A study carried out in Mato Grosso
o Sul assessed mortality and cause of death in 63 patients
ith SCD (55 had Hb SS and 8 had Hb SC), taking (n = 39) and
ot taking HU (n = 24).26 Ten (15.8%) of the patients died with a
ean age of 28.1 years, eight with Hb SS and two with Hb SC;
0% of the deaths occurred in patients not taking HU. The main
auses of death were acute respiratory failure (40%), multiple
rgan failure (20%), cardiogenic shock (20%), stroke (10%) and
eptic shock (10%).26
A prospective cohort of 104 pregnant women with SCD
egistered in the Fundac¸ão Hemominas in Belo Horizonte
howed that one-third of pregnant women had near misses
nd 4.8% died (ﬁve deaths); the causes were ACS (n = 4) and
epsis (n = 1).23
iscussion
he increases in the rates of hospitalization and death after
he implementation of neonatal screening in the state of
aranhão suggest that previously there was an underdiag-
osis of SCD and that screening, along with other factors,
ncreased ‘visibility’ of the disease in the state. Possible
xplanations for an increase both in hospitalization and
ortality rates after implementing neonatal screening are
nder-reporting of the disease due to difﬁculty of diagnosis,
nsufﬁcient hospital care, incorrect use of the international
isease classiﬁcation (ICD) code and lack of hospital registry.19
he authors from Bahia concluded that there is a lack of stud-
es correlating mortality in this genetic disorder and they high-
ighted the need for ﬁlling out death certiﬁcates correctly.20
It was evident that infection (including pneumonia and
epticemia) and ASS were the main causes of infant mortal-
ty. Moreover, the incidence of death was higher in patients
ith sickle cell anemia, the most common genotype and the
ost severe clinical presentation of the disease.21 The results
f Minas Gerais showed that neonatal screening for SCD was
ot sufﬁcient to signiﬁcantly reduce child mortality. Economic
nd social development and increase of the knowledge about
CD among healthcare professionals and family are needed to
vercome the high mortality rate.21,22
The studies conducted in the states of Rio de Janeiro25 and
ato Grosso do Sul26 reported that hydroxycarbamide therapy
ecreases mortality among patients with SCD. HU is an agent
hat stimulates fetal hemoglobin (Hb F) production and con-
ributes by diminishing the inﬂammatory and vaso-occlusive
henomena thereby reducing mortality.17,18,26 This drug is
rovided free of charge in Brazil to patients with SCD who
eet the criteria deﬁned by the Brazilian Ministry of Health
ydroxyurea Clinical Treatment Protocol. The inclusion crite-Please cite this article in press as: Arduini GA, et al. Mortality by 
http://dx.doi.org/10.1016/j.bjhh.2016.09.008
ia are the following: (1) documented diagnosis of SCD (any
enotype), (2) adults ≥18 years and children ≥ 3 years with
arental consent, (3) ability to fulﬁll clinical and laboratory 1 6;x x x(x x):xxx–xxx 3
monitoring and (4) at least one of the following in the preced-
ing 12 months: ≥3 painful events requiring medical treatment,
≥one episode of ACS, prior stroke or transient ischemic attack,
one serious or recurrent episodes of postpubertal priapism, or
a Hb concentration <6 g/dL on three separate occasions.27 Data
from a longer (17 years of follow-up) non-randomized prospec-
tive study of adults with SCD registered 13 (9.9%) deaths in the
HU group and 49 (24.6%) in the group not treated with HU. The
probability of 10-year survival was 86% and 65% for HU and
non-HU patients, respectively.17 Hydroxycarbamide therapy
was also associated with decreased mortality among children
with SCD.25
Pregnant women with SCD have a higher risk of maternal
and fetal mortality when compared to those with SCT or the
population in general.23,28,29 A research that assessed the evo-
lution of pregnancies in 34 women with SCD for a period of
12 years reported 26.6% of miscarriages, seven fetal losses (3
stillbirths and 4 miscarriages) and only one maternal death
(2.9%) in the postpartum period due to ACS.28 A study car-
ried out in France, aiming to describe maternal mortality in
women with SCD from 1996 to 2009 reported 15 deaths, with
two of them by septic shock during pregnancy and 13 occurring
in the postpartum period, with the same number of deaths
being attributed directly to SCD. Ten women were homozy-
gous (Hb SS) for SCD, and ﬁve were composite heterozygotes.29
A recent review of the literature showed that maternal and
fetal mortality rates during pregnancy can reach 11.4% and
20%, respectively.30
Studies carried out in other countries also presented data
about mortality by SCD. One of them, carried out in Africa,
reported 86 deaths (5.7%; n = 20 and 23.3% hospital deaths)
among 1516 patients with SCD. Two deaths occurred in chil-
dren under the age of two, 22 in children under ﬁve, 47 deaths
in the 5–19 age range and 15 in over 20-year-old individuals.31
Another study carried out in Amsterdam, before the Neonatal
Screening Program in the Netherlands, identiﬁed 298 children
with SCD (189 with Hb SS, 72 with Hb SC, 20 with Hb S/+ and
17 with Hb S/0) between 1985 and 2007. During the obser-
vation period, 12 patients (4%) died, with sepsis/meningitis
(n = 4; 33%) and stroke (n = 3; 25%) being the main causes. Three
deaths occurred by meningitis (Hb SC, Hb S/ and Hb SS),
one by sepsis (Hb SS) and three fatal strokes occurred in over
10-year-old patients (two with Hb SS and one with Hb SC).
Concerning the age at death, four children (33%) under the
age of 3 died, three (25%) were between 3 and 18 years old
and ﬁve (42%) were over the age of 18.32 This study showed
that the mean age at death was 11.3 years and one out of
40 children with SCD in the Netherlands does not survive
until adulthood.32 In Jamaica, of 75 young adult patients with
SCD, 11 (14.7%) died, with sepsis being the main cause of
death.33 The Neonatal Screening Program in New York iden-
tiﬁed 21 (1.1%) deaths after the diagnosis of SCD from 2000
to 2009. Of these, 14 occurred in under 2-year-old children
and seven in children aged between 2 and 9 years old. Of the
total deaths, 16 occurred in children with Hb SS or Hb S/0
and ten were related to SCD. The deaths of the other ﬁve chil-
dren with Hb SC were not related to the pathology in question.sickle cell disease in Brazil. Rev Bras Hematol Hemoter. 2016.
Another interesting ﬁnding of this research was that SCD was
mentioned on the death certiﬁcate in only 57% of the cases
(n = 12).34 A recent study in the USA about the mortality rate
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of children and adults with SCD showed a decrease in the
ﬁrst group (3%) and an increase in the second (1%) during the
same period of 26 years (1979–2005).35 Between 1990 and 2010
in Iran, the overall deaths attributed to hemoglobinopathies
decreased from 0.51% to 0.36% of total deaths.36 A retrospec-
tive study showed that infections were the commonest cause
of death in Nigerian SCD patients.37 The mean age at death
was 21.3 years (range: 1–47 years) with peak mortality in the
2nd and 3rd decades of life. Infections and thromboembolic
phenomenon were the main causes of death, in 78% and 37%
of the cases, respectively. This was followed closely by ane-
mia  alone or in combination with acute sequestration crises
in 31% of patients.37
Conclusions
In summary, there are few published studies on mortality by
SCD in Brazil, most of which are from the state of Minas Gerais.
This study shows the importance of developing more  studies
on death related to SCD, so that it may be possible to proﬁle
the gene carrier and give health professionals more data so
that they can strategize to provide more  effective assistance
to these individuals. The main causes of death are infection,
ASS and ACS.
Infections are the most common causes of death in SCD
patients in Brazil with the majority occurring in patients with
sickle cell anemia, the most common genotype and the most
severe clinical presentation of the disease. Studies show that
despite the early diagnosis of SCD by the Neonatal Screening
Program and the use of preventive and therapeutic measures
(penicillin, immunization and hydroxyurea), mortality by SCD
on the world stage is still signiﬁcant. Variables such as fre-
quency, death rates or mortality coefﬁcient, age and causes
of death were not totally investigated by all researchers. This
makes it impossible to perform a more  accurate analysis of
mortality by SCD in the world.
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